The Highest Paying Life Sciences Job You Never Heard OfWhat's the highest paying job in biotech you've probably never heard of?Read the rest of this entry »
OK. That's sort of a trick kind of question, since you can't really answer it if you've never heard of it. So we'll tell you what BioSpace said the job is: Medical Science Liaison.
The site, which describes itself as a "digital hub for news and careers" in life sciences, said the ...
3D Printers Are Pharma's 'Next Great Step'3D printing came to the pharmaceutical industry two years ago when the FDA gave Aprecia Pharmaceuticals approval to use the technology to manufacture its epilepsy medication Spritam.Read the rest of this entry »
Though adoption of 3D pharmaceutical manufacturing is in its infancy, within a decade the medical application of the technology could exceed $1.9 billion, an estimate that may already be outdated as the pace of development has been accelerating steadily. Before drug companies ...
How the Pharmaceutical Industry May Track Every PillA technology most commonly linked to the cryptocurrency payment system Bitcoin, may prove to be the key to rooting out counterfeit prescription drugs.Read the rest of this entry »
Blockchain startup Chronicled and supply chain consultant, The LinkLab, last week announced a pilot "track and trace" program for the pharmaceutical industry.
The industry is under a 2023 deadline to develop and implement an electronic, interoperable system to identify and trace prescription drugs throughout the U.S ...
The Challenges of Clinical Trial RecruitingIn a world where clinical trials are becoming increasingly complex, one of the first challenges pharmaceutical companies, as well as other medical researchers, face is recruiting sufficient number of subjects to produce valid results.Read the rest of this entry »
Though getting more difficult all the time, by no means is this a new problem. Louis Lasagna, a pioneer in clinical pharmacology, came up with what is now called Lasagna's Law, which, in essence says ...
How the New Health Economy is Changing PharmaDeclaring that we're in a "New Health Economy," the global consulting firm PwC says life sciences and drug companies are facing multiple new challenges that are turning old business models on their head.Read the rest of this entry »
There are "three pivotal healthcare and pharma industry developments... that pharma companies must confront in 2017," says PwC in an article on the firm's Strategy& site. As Pwc describes them, the three are:
- The year ...
Pharma's 2016 TV Spend Topped $2.2 BillionAnyone who watches TV, especially daytime TV, couldn't help but wonder just what kind of miracle drug Humira must be. Ads for the drug aired more than 69,000 times last year.Read the rest of this entry »
In order of how much its manufacturer, AbbVie spent touting Humira's uses:
- Arthritis -- $173 million
- Crohn's and colitis -- $118 million
- Psoriasis -- $54 million.
Among the top 20 brands advertised on TV, Humira's $344 million ...
More Biotech PhDs Are Starting CompaniesThe boom in biotech funding coupled with the paucity of academic jobs is tempting young scientists to skip post-doc research in favor of heading straight into business.Read the rest of this entry »
The science journal Nature says there's a "vanguard of young biomedical scientists who have started companies instead of taking the conventional academic path and pursuing postdoctoral studies after their PhDs."
Where once investors would only fund companies started by established professors who ...
Pharma CEOs See Opportunity Ahead"Pharma's future have never looked more promising -- or more ominous." That cautionary statement topping the front page of the last report in PWC's Pharma 2020 series could still stand today as a summary of the entire pharmaceuticals and life sciences industry.Read the rest of this entry »
PWC's most recent survey of the CEOs of 87 of the largest pharmaceutical companies found optimism about the growth of their individual revenues as well as ...
Pharma Unlikely to See Recovery This YearIn a bluntly worded economic recap for the pharmaceutical industry, Evaluate Pharma had this to say:Read the rest of this entry »
"If anything can be gleaned from the first half of 2016 it is that the peak is in the past. Any hopes that the declines of the second half of 2015 might be reversed must now be put to bed, and the highs of last July be consigned to the record books."
In its ...
Drug Companies Making Millions From Off-Label Use of Orphan DrugsCharging that orphan drugs "have become a lucrative business opportunity for pharmaceutical companies," a new report suggests drug makers are gaming a system intended to spur the development of treatments that would not otherwise be profitable.Read the rest of this entry »
Funded by the insurance lobby AHIP (American Health Insurance Plans), the report says pharmaceutical companies are benefiting from the tax advantages, market exclusivity and clinical subsidies provided by the Orphan Drug Act. But many ...